



Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience

Elise Weir & James Paton

To cite this article: Elise Weir & James Paton (2019): Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience, Journal of Asthma, DOI: [10.1080/02770903.2019.1579833](https://doi.org/10.1080/02770903.2019.1579833)

To link to this article: <https://doi.org/10.1080/02770903.2019.1579833>



Published online: 22 Feb 2019.



Submit your article to this journal [↗](#)



Article views: 55



View Crossmark data [↗](#)

LETTER



Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience

Elise Weir, MBChB^a and James Paton, MD^b

^aDepartment of Respiratory Paediatrics, Royal Hospital for Children Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland; ^bSchool of Medicine, University of Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland

Introduction

Omalizumab is a recombinant monoclonal antibody (IgG1) targeting IgE for use in severe allergic asthma. However, it is not a suitable treatment in some patients because of their IgE level and/or weight [1], and a small number of eligible patients do not respond to it [2]. Mepolizumab, an anti-interleukin-5 (IL-5) monoclonal antibody is an emerging therapy approved for use in adults with severe refractory eosinophilic asthma [3,4] and has been shown to reduce asthma attacks in adults and adolescents [5–7]. Mepolizumab has been accepted by NICE and the Scottish Medicines Commission for restricted use as an add-on treatment for severe refractory eosinophilic asthma in adult patients, and more recently for use in children from 6 years in the EU [3,8]. Although 28 adolescents who were 12 years and upwards were eligible for inclusion in the pivotal studies, only 19 adolescents aged 12–17 years old were treated with mepolizumab [9–11].

In our experience, children with severe eosinophilic asthma who are poorly responsive to standard therapies, are not eligible for omalizumab or fail to respond to it, are clinically difficult to manage. Our pediatric center obtained local approval for use of mepolizumab as an unlicensed medicine in such adolescents with severe eosinophilic asthma. Here, we review our experience of mepolizumab on acute asthma attacks, asthma control (Asthma Control Test, (ACT)) [12], pulmonary function (fractional exhaled nitric oxide concentration (FeNO) and forced expiratory volume in 1 s (FEV₁)), blood eosinophil count, and quality of life (Pediatric Asthma Quality of Life Questionnaire (PAQLQ)). We performed an initial evaluation after 4 months as is recommended for omalizumab [13] and after 12 months treatment.

Methods

Study participants

We retrospectively analyzed data from adolescents offered mepolizumab at the Royal Hospital for Children, Glasgow between October 2016 and January 2018. Adolescents were offered mepolizumab if they had severe eosinophilic asthma and were not eligible for omalizumab ($n = 7$).

Eosinophilic asthma was defined as a blood eosinophil count >300 cells/ μ L or fractional exhaled nitric oxide concentration (FeNO) ≥ 50 ppb in the previous year [9]. All adolescents received high-dose inhaled corticosteroids (ICS), long-acting beta-adrenoceptor agonist (LABA) and had a history of ≥ 3 severe asthma attacks needing systemic corticosteroids in the previous year. Six adolescents received leukotriene receptor antagonists, three received slow-release oral theophylline and four received daily oral steroids. All had low ACT scores (mean 10.4) prior to mepolizumab.

Each patient received 12 mepolizumab doses of 100 mg administered subcutaneously at monthly intervals, with evaluation after 4 and 12 doses. Long-term medications were not adjusted during mepolizumab treatment.

Pulmonary function testing

Pulmonary function was measured using a Jaeger Masterscreen Body Plethysmograph (Jaeger V5.4, Germany) and FeNO measured with an electrochemical analyzer (Aerocrine NIOX MINO, Sweden) by an experienced pediatric physiologist in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) standards [14–16].

CONTACT Elise Weir, MBChB  elise_yu@doctors.org.uk  Department of Respiratory Paediatrics, Royal Hospital for Children, 1345 Govan Road, Glasgow G51 4TF.

Color versions of one or more figures in the article can be found online at www.tandfonline.com/ijas.

© 2019 Taylor & Francis Group, LLC

Consent

As mepolizumab is an unlicensed drug in adolescents, informed verbal consent was obtained. As this study was a retrospective review of results from our clinical practice, we did not seek informed consent for review of anonymised patient data.

Statistical analysis

Data expressed as means and SDs. Forced expiratory volume in 1 s (FEV₁) expressed as z-scores using GLI reference ranges [17].

Results

Seven adolescents (mean age 13.9 ± 1.9 , range 11–17 years; 5 males, 2 females; mean weight 62.0 ± 10.04 kg, range 51–77 kg) were offered mepolizumab. Four had IgE-weight combinations above the manufacturer's recommended treatment boundaries for omalizumab (mean IgE level 1512 IU/ml, range 1031–2229 IU/ml). Three had previously received omalizumab: one failed to respond and two developed allergic reactions resulting in treatment discontinuation.

Blood eosinophil count evaluated after 3 or 4 mepolizumab doses and decreased in all patients (mean pretreatment $0.8 \pm 0.64 \times 10^9$ cells/L to mean $0.1 \pm 0.06 \times 10^9$ cells/L at the 3rd or 4th mepolizumab dose). FEV₁ z-score improved in only 2/7 patients (29%) after 4 mepolizumab doses (mean Δ FEV₁ z-score -0.2 ± 0.68). ACT score improved in 5/7 (71%) after 4 mepolizumab doses with a mean Δ ACT score of 3.0 ± 4.55 . PAQLQ scores were assessed after the initial three mepolizumab doses and improved or remained static in 5/7 patients (71%), mean Δ PAQLQ score of 0.9 ± 1.84 .

After 12 months of mepolizumab, FEV₁ z-score improved from baseline in 2/7 (29%) (mean Δ FEV₁ z-score -0.5 ± 1.2). In 3/7 patients (43%), the FEV₁ z-score deteriorated with a year of mepolizumab treatment and remained static in 2/7 patients. ACT improved from baseline in only 3/7 patients (43%), with a mean Δ ACT score 1.7 ± 7.25 . Mean Δ FeNO after four mepolizumab doses was -15 ± 29 ppb and after 12 doses was -37 ± 126 ppb. No serious adverse effects reported.

Episodes of asthma attacks in relation to treatment timelines for each patient are shown in Figure 1. Mean number of asthma attacks requiring high dose




Figure 1. Illustration of asthma attacks over time. The blue part of each timeline represents 12 months pre-mepolizumab and yellow represents 12 months during mepolizumab treatment (each subunit being 1 month), with the vertical black line highlighting commencement of mepolizumab. Vertical green lines highlight when mepolizumab was given. The red arrows represent hospitalizations for severe asthma attacks and the blue arrows represent patient reported asthma attacks requiring a course of oral steroids.

oral steroids in the 12 months prior to mepolizumab was 5.0 ± 1.73 . Four patients required hospitalization for severe attacks during this time: 2 admitted once, 1 admitted twice, 1 admitted three times. In the 12 months prior to commencing mepolizumab treatment, the mean number of hospitalizations for these 4 patients was 1.8 ± 0.96 . During treatment, only 1 patient required 2 hospitalizations for asthma attacks after 1 and 11 mepolizumab doses. There was reduced frequency of severe attacks requiring high-dose oral steroids (mean 1.1 ± 1.07 after 4 doses and mean 3.1 ± 3.13 after 12 doses) with 1 patient (14%) having no severe attacks during mepolizumab treatment. Although there was an overall improvement in the frequency of hospitalizations and severe attacks during mepolizumab, two patients (patients 6 and 7) appear to be non-responders.

Discussion

In these adolescents with eosinophilic asthma not eligible for omalizumab or who had not benefited from it, mepolizumab reduced asthma attacks in frequency or severity for the majority, similar to findings reported in adults and limited data available in adolescents [5,6,7]. We confirmed that while mepolizumab reduced eosinophils to zero, those with a higher baseline eosinophil blood count did not respond better. There was less response of FeNO to mepolizumab, consistent with findings by Halder et al [18] and Pavord et al [5], confirming a weak correlation between these markers and suggesting two different inflammatory pathways [19]. We found that mepolizumab did not bring any consistent improvement in lung function, ACT or PAQLQ scores. However, all patients subjectively reported positive feedback on their asthma control. Review at 4 and 12 months highlight that a 4-month evaluation as is performed for omalizumab, is not sufficient time to assess the effect of mepolizumab on asthma attacks and we recommend a 12-month evaluation.

Limitations

This was a retrospective review of a small number of adolescents managed with mepolizumab within clinical practice with no control group.

Conclusion

Mepolizumab 100 mg given subcutaneously at monthly intervals was well tolerated in adolescents

with severe eosinophilic asthma who were either ineligible for or who had failed on omalizumab. Over a 12-month period of evaluation, it had a positive effect on reducing risk of asthma exacerbations. Further studies comparing the effectiveness of omalizumab and mepolizumab in children who are eligible for both will be required to determine who best to use these drugs in children with severe asthma.

Acknowledgements

We would like to thank Sister Phillipa Madge, Paediatric Asthma Nurse Specialist who assessed our patients during mepolizumab treatment and our Respiratory Physiology team who monitored lung function.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

1. Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. *J Allergy Clin Immunol Pract* 2013;160:102–110.
2. Kallieri M, Papaioannou A, Papathanasiou E, et al. Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. *Postgrad Med* 2017;129:598–604.
3. National Institute for Health and Care Excellence (2017) Mepolizumab for treating severe refractory eosinophilic asthma. NICE technology appraisal guidance (TA431).
4. Scottish Medicine Consortium (2016) Mepolizumab 100mg powder for solution for injection (Nucala®). SMC No. (1149/16).
5. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial. *Lancet* 2012;380:651–659.
6. Ortega HG, Liu M, Pavord I, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 2014;371:1198–1207.
7. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med* 2014;371:1189–1197.
8. GlaxoSmithKline. European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma. London, UK: GlaxoSmithKline; 30 Aug 2018. Available from: <https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma/> [last accessed September 2018].
9. GSK Clinical Study Report MEA115588. Available from: <https://www.gsk-clinicalstudyregister.com/files2/>

- [gsk-115588-clinical-study-report-redact.pdf](#) [last accessed July 2018].
10. GSK Clinical Study Report MEA 115575. Available from: <https://www.gsk-clinicalstudyregister.com/files2/gsk-115575-clinical-study-report-redact.pdf> [last accessed July 2018].
 11. GSK Clinical Study Report MEA112997. Available from: <https://www.gsk-clinicalstudyregister.com/files2/gsk-112997-clinical-study-report-redact.pdf> [last accessed July 2018].
 12. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;113:59–65.
 13. National Institute for Health and Care Excellence (2013) Omalizumab for treating severe persistent allergic asthma. NICE technology appraisal guidance (TA278).
 14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005;26: 319–339.
 15. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, et al. Standardisation of the measurement of lung volumes. *Eur Respir J* 2005;26: 511–522.
 16. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J* 2005;26:720–735.
 17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40:1324–1343.
 18. Halder P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* 2009;360:973–984.
 19. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. *J Allergy Clin Immunol* 2013;132:821–827.